Vericel Corp (NASDAQ:VCEL) shares traded down 5.9% on Monday . The company traded as low as $16.56 and last traded at $16.70. 548,325 shares were traded during trading, a decline of 16% from the average session volume of 653,455 shares. The stock had previously closed at $17.74.

VCEL has been the subject of several recent analyst reports. Zacks Investment Research raised Vericel from a “hold” rating to a “buy” rating and set a $22.00 price objective for the company in a report on Tuesday, March 5th. BidaskClub lowered Vericel from a “hold” rating to a “sell” rating in a report on Saturday, March 30th. Oppenheimer boosted their price objective on Vericel from $23.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, May 8th. Finally, Needham & Company LLC lowered Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective for the company. in a report on Thursday, February 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $22.98.

The company has a debt-to-equity ratio of 0.24, a current ratio of 8.47 and a quick ratio of 8.16. The firm has a market capitalization of $740.54 million, a P/E ratio of -121.71 and a beta of 2.93.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The company had revenue of $21.81 million during the quarter, compared to analyst estimates of $22.51 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. Vericel’s revenue was up 21.0% on a year-over-year basis. On average, analysts anticipate that Vericel Corp will post 0.08 earnings per share for the current fiscal year.

In other news, CFO Gerard J. Michel sold 10,000 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $20.02, for a total transaction of $200,200.00. Following the completion of the transaction, the chief financial officer now owns 122,249 shares of the company’s stock, valued at $2,447,424.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven C. Gilman sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $18.02, for a total value of $135,150.00. The disclosure for this sale can be found here. Insiders have sold 58,125 shares of company stock valued at $1,034,900 in the last three months. 4.50% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in VCEL. Emerald Advisers LLC bought a new stake in Vericel in the 1st quarter worth approximately $7,295,000. Teachers Advisors LLC lifted its position in Vericel by 531.8% in the 3rd quarter. Teachers Advisors LLC now owns 446,296 shares of the biotechnology company’s stock worth $6,315,000 after buying an additional 375,654 shares during the last quarter. Vanguard Group Inc lifted its position in Vericel by 18.2% in the 3rd quarter. Vanguard Group Inc now owns 2,363,346 shares of the biotechnology company’s stock worth $33,441,000 after buying an additional 363,705 shares during the last quarter. Vanguard Group Inc. lifted its position in Vericel by 18.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,363,346 shares of the biotechnology company’s stock worth $33,441,000 after buying an additional 363,705 shares during the last quarter. Finally, Osterweis Capital Management Inc. bought a new stake in Vericel in the 1st quarter worth approximately $5,334,000. Institutional investors own 84.21% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.mareainformativa.com/news/2019/05/15/vericel-vcel-trading-down-5-9.html.

About Vericel (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Recommended Story: Special Dividends

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.